Boosting regional integration for COP D care through guided implementation and audit of post exacerbation transition bundle

Trial Identifier: D5980L00025
Sponsor: AstraZeneca
Start Date: November 2024
Primary Completion Date: August 2026
Study Completion Date: August 2026
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anyang, China
China Baise, China
China Beijing, China
China Bijie, China
China Changsha, China
China Chenzhou, China
China Chifeng, China
China Chuzhou, China
China Deyang, China
China Fuyang, China
China Hangzhou, China
China Hefei, China
China Jieyang, China
China Jining, China
China Jiujiang, China
China Kaiyuan, China
China Langfang, China
China Langzhong, China
China Leping, China
China Nanchang, China
China Nanchong, China
China Neijiang, China
China Qiannan, China
China Qujing, China
China Sanmenxia, China
China Shaoyang, China
China Suzhou, China
China Tengzhou, China
China Tieling, China
China Wenzhou, China
China Xiangtan, China
China Xiaogan, China
China Xinyang, China
China Yancheng, China
China Yichang, China
China Yuling, China
China Zaoyang, China